Polymeric Nanosystems: A Breakthrough Approach to Treating Inflammation and Inflammation Related Diseases

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmacology

Background:

• Inflammation processes cause significant damage and lead to numerous inflammation-related diseases (IRD), including cancer and neural, vascular, and pulmonary conditions.
• Conventional anti-inflammatory drugs (AID) face limitations such as high doses, toxicity, low bioavailability, poor solubility, and side effects, hindering effective treatment.
• Polymeric nanosystems (PS) have emerged as a promising technology to address these challenges in IRD treatment.

Purpose of the Study:

• To provide an overview of polymeric nanosystems (PS) for treating inflammation-related diseases (IRD).
• To discuss the properties, preparation, and applications of three classes of PS: dendrimers, polymeric micelles/nanoparticles, and polymeric filomicelles.
• To highlight the potential of PS to overcome limitations associated with conventional anti-inflammatory drugs (AID).

Main Methods:

• Review and synthesis of current literature on polymeric nanosystems for anti-inflammatory drug delivery.
• Categorization of PS into dendrimers, polymeric micelles/nanoparticles, and polymeric filomicelles.
• Analysis of PS properties, preparation methods, and their specific applications in treating various inflammation-related diseases.

Main Results:

• Polymeric nanosystems (PS) demonstrate versatility, biocompatibility, low toxicity, and tunable properties for effective AID encapsulation and targeted delivery.
• Specific classes of PS, including dendrimers, polymeric micelles, nanoparticles, and filomicelles, show potential in overcoming the limitations of traditional AID.
• PS enable precise delivery of anti-inflammatory agents to targeted sites, enhancing therapeutic efficacy for IRD.

Conclusions:

• Polymeric nanosystems (PS) represent a significant advancement in the treatment of inflammation-related diseases (IRD) by improving anti-inflammatory drug (AID) delivery.
• The versatility and targeted delivery capabilities of PS offer a safer and more effective therapeutic strategy compared to conventional AID.
• The increasing attention and development in PS formulations suggest a growing role in clinical practice for managing IRD.